ClinicalTrials.gg
Active, not recruitingNCT05568459Honey-BUpdated Nov 9, 2026

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

An observational study in Hemophilia B, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 17 sites in 4 countries. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Regeneron Pharmaceuticals · Observational

Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11
Ages
16 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies in Hemophilia B with a site in United States — 16 open to participants now, 22 under way, 9 of them phase 3. Hemophilia B · United States.

Enrollment
32nd of 39
11 · median 64
Started
2024
with 5 others
Observational
39 of 120
7 open now
Primary completion
2026-11
later than 6 of 21 live
Registered
103rd of 120
by date

Among the 120 studies in Hemophilia B with a site in United States, this one is the 32nd largest by enrollment of the 39 observational ones that give a count, is one of 6 that started in 2024, is one of 39 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 103rd registered.

Hemophilia B

292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.

Browse Hemophilia B studies →

Open to participants now

16 of the 120 studies in Hemophilia B with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Hemophilia B studies recruiting now, 18 (58%) set no upper age limit and 11 (35%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Hemophilia B with a site in United States, or all of them as a file.
02

Study summary

This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program to understand and treat Hemophilia B with a potential experimental new therapy in the future. There is no obligation to agree to taking part in this future study.

The study is looking to answer several other research questions to help understand each participant's individual disease characteristics, including:

  • How often to use FIX replacement therapy, both on a regular basis (prophylaxis) and as needed to treat bleeding events
  • Measurement of FIX activity (factor IX is a clotting factor) by different laboratories using different types of tests in Hemophilia B participants
  • Possible complications from the FIX replacement therapy the patient receives (usual standard of care will continue to be used)
  • How quality of life is affected by Hemophilia B
  • How joint health is affected by Hemophilia B
  • How often the participant visits the emergency room, urgent care center, physician's office, hospital, or has a telemedicine visit as a result of bleeding events
  • Whether the body makes antibodies (a protein produced by the body's immune system) against the FIX replacement therapy you receive, which could make the drug less effective or could lead to side effects
03

Conditions studied

  • Hemophilia B

Browse trials for

Keywords

  • FIX replacement therapy
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male patients with Hemophilia B with a history of FIX:C ≤2% or a documented genotype known to produce severe hemophilia B on current FIX Replacement Therapy prophylaxis

Eligibility criteria

Key Inclusion Criteria:

  1. Previous experience with FIX therapy (≥50 documented exposure days to a FIX protein product such as recombinant, plasma-derived or extended half-life FIX product) with a current stable prophylaxis regimen for >2 months prior to enrollment and intention to use FIX replacement therapy for the duration of the study
  2. No known to FIX replacement product
  3. Willing to be contacted about a potential future clustered regularly interspaced short palindromic repeats (CRISPR)-based Factor 9 (F9) gene insertion clinical trial in which they may have the opportunity to screen for enrollment

Key Exclusion Criteria:

  1. History of any coagulation disorder; requires anticoagulant therapy
  2. Lack of adherence with documentation of bleeds and/or prophylaxis replacement therapy administration in the opinion of the investigator, based on medical history
  3. History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or more occasions, as defined in the protocol
  4. Bethesda inhibitor titer greater than the (ULN) at screening
  5. Any detectable pre-existing antibodies to the Adeno-associated virus serotype 8 (AAV8) capsid; as measured by an assay at prescreening, as defined in the protocol
  6. Is positive for or C at screening, as defined in protocol
  7. If any of the following pre-existing diagnoses are documented:

    • Cholestatic liver disease
    • Liver cirrhosis
    • Portal hypertension; or
    • Splenomegaly; or
    • Hepatic encephalopathy
  8. History of arterial or venous thrombo-embolic events, as defined in the protocol
  9. History of cardiovascular, respiratory, hepatic, renal (including nephrotic syndrome), gastrointestinal (including protein-losing enteropathy), endocrine, hematological (including thrombophilia), psychiatric, or neurological disease, as assessed by the investigator that may confound the results of the study or poses an additional risk to the participant by study participation
  10. Previously received of any AAV-gene based therapy with a marketed gene therapy or in a clinical trial or intent to receive approved or AAV-gene based therapy during the study period

NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Male participants with hemophilia B on current FIX Replacement Therapy prophylaxis or a documented genotype known to produce severe hemophilia B

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    No study treatment will be administered in this study.

06

What researchers measure

Primary outcomes

  1. Annualized bleeding rate (ABR)

    Time frame: At least 26 Weeks Up to 96 weeks

Secondary outcomes

  1. Annualized utilization (IU/kg) of FIX replacement therapy

    Time frame: Up to 96 Weeks

  2. FIX functional (coagulant) activity (FIX:C) in participants on prophylaxis FIX replacement therapy

    FIX:C includes pre-dose and average activity

    Time frame: Through the end of the study, approximately 96 Weeks

  3. Difference of FIX:C in participants on prophylaxis FIX replacement therapy by one-stage and chromogenic assays

    Time frame: Through the end of the study, approximately 96 weeks

  4. Difference of FIX:C between one-stage assay and chromogenic substrate assay by laboratory in participants on prophylaxis FIX replacement therapy

    Time frame: Through the end of the study, approximately 96 weeks

  5. Difference of FIX:C between laboratories by assay (one-stage assay and chromogenic substrate assay) in participants on prophylaxis FIX replacement therapy

    Time frame: Through the end of the study, approximately 96 weeks

  6. Incidence of adverse event (AEs)

    Time frame: Through the end of the study, approximately 96 Weeks

  7. Severity of AEs

    Time frame: Through the end of the study, approximately 96 Weeks

  8. Hemophilia Quality of Life (Haemo-Qol-A) total and individual domain scores

    The Haemo-QoL-A is a self-reported Hemophilia-specific health-related quality of life questionnaire which consists of 41 questions covering 6 domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact, and Treatment Concerns). Items are answered on a 6-point Likert-type scale, ranging from 0 (None of the time) to 5 (All of the time). Higher scores mean better health-related quality of life or less impairment.

    Time frame: Up to 96 Weeks

  9. Hemophilia Activities List (HAL) total and individual scores

    HAL measures of the impact of Hemophilia on functional abilities in adults. The questionnaire consists of 42 items across 7 domains. Each item is rated on a scale of 1 (Impossible) to 6 (Never). Higher scores represent lower levels of activity limitations.

    Time frame: Up to 96 Weeks

  10. European Quality of Life 5 Dimensions 3-levels (EQ-5D-3L) score

    EQ-5D-3L health questionnaire is a participant/relative answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. the status of each dimension had 3 possible responses (1 =no problem, 2 some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition.

    Time frame: Up to 96 Weeks

  11. Hemophilia Joint Health Score (HJHS) total and individual scores per joint

    The examination involves a physical assessment of elbow, knee, and ankle joints. Individual joints are scored based on duration and presence of swelling, joint pain, flexibility, muscle atrophy, strength, and overall gait. The HJHS is a validated 11-item scoring tool based on radiologic and clinical evaluation, sensitive to detect early signs and minor changes. HJHS ranges from 0 to 124. Higher values in the HJHS represent worse situation for the participant.

    Time frame: Up to 96 Weeks

  12. Annualized medically attended visit (MAV) rate for any reason

    The annual rate of MAVs including emergency room (ER) visits, urgent care center visits, physician's office visits, telemedicine visits, or hospitalizations related to bleeds treated on-demand with FIX replacement therapy

    Time frame: Up to 96 Weeks

  13. Detection of antibodies to adeno-associated virus (AAV) capsid proteins

    Time frame: Up to 96 Weeks

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.

Of 42 observational studies under Hemophilia B, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 105. This study's planned 34 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Oct 5, 2022
StartActual
Jan 17, 2024
Primary completionEst.
Nov 20, 2026was Aug 2026
CompletionEst.
Nov 20, 2026was Aug 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 21, 2026→Nov 20, 2026
Nov 9, 2026
Study completion
Aug 21, 2026→Nov 20, 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Aug 21, 2026→Nov 20, 2026
    Study completion Aug 21, 2026→Nov 20, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05568459
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Jan 17, 2024
Primary completion
Nov 20, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion